ATG4B and neoplasm: The findings demonstrate a robust downregulation of ATG-4B expression across various treatment conditions, with BCc1 and cyclophosphamide showing particularly strong effects, further implicating autophagy-related genes as potential therapeutic targets in the tumor microenvironment.